New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2012
17:24 EDTMRK, GS, GSK, SNY, ABTGoldman Sachs hired to explore Bausch & Lomb sale, Bloomberg reports
Goldman Sachs (GS) has been hired by Warburg Pincus to explore a sale of Bausch & Lomb, the company's eye-care division, and Warburg is said to be seeking at least $10B for the business, according to a Bloomberg report that cites sources familiar with the matter. The report says that Goldman contacted Sanofi (SNY), GlaxoSmithKline (GSK), and Merck (MRK) this month, and that Abbot Laboratories (ABT) will be among the other companies contacted, according to a source. Reference Link
News For GS;ABT;GSK;MRK;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
January 16, 2015
09:47 EDTGSGoldman Sachs says firm SLR compliant with regulatory minimum
09:42 EDTGSGoldman Sachs CFO says FICC market-making conditions 'difficult' in Q4
Subscribe for More Information
09:37 EDTGSActive equity options trading
Subscribe for More Information
09:12 EDTGSOn The Fly: Pre-market Movers
Subscribe for More Information
09:04 EDTGSConocoPhillips names John Faraci, Argun Murti to board
ConocoPhillips (COP) announced that John Faraci, former chairman and CEO of International Paper (IP), and Arjun Murti, former partner at Goldman Sachs (GS), have been elected to its board of directors. The election of Faraci and Murti increases the total number of ConocoPhillips directors to 12, 11 of which are outside directors.
08:31 EDTGSKGlaxoSmithKline CEO says more IPOs like ViiV could happen, Retuers says
Subscribe for More Information
08:02 EDTGSGoldman Sachs down 1.5% following Q4 earnings report
Subscribe for More Information
07:55 EDTGSGoldman Sachs reports Q4 net gain on credit spread changes of $82M
Subscribe for More Information
07:44 EDTGSGoldman Sachs CEO says 'pleased' with 2014 performance
“We are pleased with our performance during a year characterized by mixed global economic and financial conditions. The depth of our global client franchise and our continued discipline on expenses and capital management produced a solid return for our shareholders. Looking ahead, we see evidence of a continued pick up in momentum for the global economy that will improve the opportunity set for 2015,” said Goldman Sachs CEO Lloyd Blankfein. Goldman reports book value per common share was $163.01 and tangible book value per common share was $153.79, both approximately 7% higher compared with the end of 2013 and approximately 1% higher compared with the end of the third quarter of 2014.
07:41 EDTGSGoldman Sachs says compensation/benefits costs essentially unchanged in FY14
Subscribe for More Information
07:39 EDTGSGoldman Sachs reports Q4 Investment Banking revenue $1.44B
Subscribe for More Information
07:36 EDTGSGoldman Sachs reports Q4 EPS $4.38, consensus $4.32
Subscribe for More Information
January 15, 2015
15:14 EDTGSNotable companies reporting before tomorrow's open
Subscribe for More Information
15:03 EDTGSGoldman Sachs technical notes ahead of results
The shares have been in a downtrend since the stock hit its 52-week high of $198.06 in early December of last year. If the downtrend continues following earnings, there are some important support levels to watch as potential downside objectives. A first major test may come at the 200-day moving average, last at $175.79. If that support failed to hold, a pivot low at $171.26 would be next support. That pivot was from the October market lows. Next support thereafter would be at $168.02. If there is more bullish news than traders currently appear to expect, the following resistance levels could become upside objectives: $180.80, $183.96, $186.58, and $189.99.
14:31 EDTGSKMylan launches generic Epivir-HBV tablets
Mylan (MYL) announced the U.S. launch of its Lamivudine Tablets, 100 mg, which is the generic version of GlaxoSmithKline's (GSK) Epivir-HBV. Mylan received final approval from the U.S. FDA for its Abbreviated New Drug Application for this product, which is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation. Lamivudine Tablets, 100 mg, had U.S. sales of approximately $18.1M for the 12 months ending September 30, 2014, according to IMS Health. Currently, Mylan has 284 ANDAs pending FDA approval representing $109.1B in annual brand sales, according to IMS Health. Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $29.3B in annual brand sales, for the 12 months ending June 30, 2014, according to IMS Health.
14:20 EDTGSGoldman Sachs January 177 straddle priced for 2.4% movement into Q4
11:20 EDTMRKGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
08:36 EDTGSKOncoMed enrolls first biomarker-selected patient in Notch1 antibody Phase trial
Subscribe for More Information
07:59 EDTMRKAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information
06:21 EDTGSGoldman Sachs helped Apollo in Caesar's restructuring deal, NY Post reports
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use